Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic - 06/06/23
, Thomas Pierret b, Maurice Pérol c, François Bettega d, Justin Benet a, Natacha Denis a, Denis Moro-Sibilot a, Aurélie Swalduz c, Anne-Claire Toffart a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
The COVID 19-pandemic has led physicians to change their approach to treating non-small cell lung cancer (NSCLC) to reduce hospital stays for patients.
Objectives |
We aimed to assess the toxicity and efficacy of extended interval (EI) dosing of immune checkpoint inhibitors (ICIs) compared to standard dosing (SD).
Methods |
In this retrospective two-center study, we included patients with stage III/IV NSCLC who were treated with ICIs with or without maintenance pemetrexed during the month before March 2020. Adverse events and efficacy were collected until June 2021. Toxicity and survival were assessed using multivariate Cox models.
Results |
Among the 134 patients identified (8 stage III and 126 stage IV; 66 first line and 60 second or subsequent lines), 70.9% received EI dosing. In the EI group, 12.6% of patients developed grade 3 or 4 immune-related adverse events versus 15.4% in the SD group (P- value = 0.8). Treatment was definitively discontinued due to toxicity in 9 patients in the EI group and in 5 in the SD group (P-value =0.5). Overall survival was not associated with dosage regimen or toxicity analyzed as a time-dependent variable.
Conclusions |
Our study suggests that EI dosing of ICIs did not affect toxicity and overall survival in lung cancer patients.
Le texte complet de cet article est disponible en PDF.Keywords : Lung cancer, Immune checkpoint inhibitors, COVID 19-pandemic, Immune-related toxicity
Abbreviations : FDA, PD-L1, COVID, NSCLC, irAE, CTCAE, ECOG, SD, EI, ICI, OS, PFS, IQR, 95% CI
Plan
Vol 83
Article 101004- juin 2023 Retour au numéro
Article précédent
- Impact of biomass fuel smoke on respiratory health of children under 15 years old in Madagascar
- Nolwenn Jestin-Guyon, El Hassane Ouaalaya, Michel Tiaray Harison, Kiady Ravahatra, Jocelyn Rakotomizao, Rondro Nirina Raharimanana, Joelson Lovaniaina Rakotoson, Jobeline Rajaoarifetra, Jean-Claude Andriamihaja Rakotoarisoa, Giannie Rasamimanana, Charlin Randriamananjara, Bakoly Ravalison, Ange Andrianarisoa, Andrianaivo Ralison, Raoelina Andriambololona, Denis Charpin, Jean De Dieu Marie Rakotomanga, Iantsoatiana Davidson Rakotondrabe, Marie Odette Rasoafaranirina, Zisler Michael Rakotondravola, Aglaé Rakotoson, Jean Robert Rakotondriaka, Anjara Nandimbiniaina, Orelys Ratsirahonana, Patricia Feno, Mampionona Razafindramboa, Brigitte Rahoelina, Jean-Marie Tschopp, Martial Coutaz, Stéphane Garrone, Pierre L'Her, Chantal Raherison-Semjen
- Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study
- Pierre Thoré, Jean Staentzel, Simon Valentin, Anne Guillaumot, Christine Selton-Suty, Emmanuel Gomez, François Chabot, Ari Chaouat
Bienvenue sur EM-consulte, la référence des professionnels de santé.